Preo Pharma ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 15.0% 16.4% 21.7%  
Credit score (0-100)  0 0 13 10 4  
Credit rating  N/A N/A BB BB B  
Credit limit (kDKK)  0.0 0.0 -0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -161 295 -41.3  
EBITDA  0.0 0.0 -161 295 -41.3  
EBIT  0.0 0.0 -161 295 -41.3  
Pre-tax profit (PTP)  0.0 0.0 -163.1 251.0 -54.3  
Net earnings  0.0 0.0 -120.1 188.7 -54.3  
Pre-tax profit without non-rec. items  0.0 0.0 -163 251 -54.3  

 
See the entire income statement

Balance sheet (kDKK) 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 -80.1 109 54.3  
Interest-bearing liabilities  0.0 0.0 178 229 228  
Balance sheet total (assets)  0.0 0.0 132 377 344  

Net Debt  0.0 0.0 67.7 -148 -115  
 
See the entire balance sheet

Volume 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -161 295 -41.3  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 132 377 344  
Balance sheet change%  0.0% 0.0% 0.0% 184.4% -8.7%  
Added value  0.0 0.0 -161.0 294.9 -41.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 1.0 -1.0  

Profitability 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -75.7% 111.1% -11.5%  
ROI %  0.0% 0.0% -90.4% 101.8% -13.3%  
ROE %  0.0% 0.0% -90.7% 156.5% -66.7%  

Solidity 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  0.0% 0.0% -37.7% 28.8% 15.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -42.1% -50.2% 279.4%  
Gearing %  0.0% 0.0% -222.4% 210.5% 420.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 2.4% 5.6% 5.7%  

Liquidity 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  0.0 0.0 0.6 1.4 1.2  
Current Ratio  0.0 0.0 0.6 1.4 1.2  
Cash and cash equivalent  0.0 0.0 110.4 376.5 343.6  

Capital use efficiency 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -80.1 108.6 54.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
N/A
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0